Loading clinical trials...
Loading clinical trials...
A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer
Conditions
Interventions
Carboplatin
Paclitaxel
+1 more
Locations
5
United States
Moffitt Cancer Center at Tampa General Hospital
Tampa, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Case Western Reserve University
Cleveland, Ohio, United States
Lake University Ireland Cancer Center
Mentor, Ohio, United States
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, United States
Start Date
August 1, 2004
Primary Completion Date
April 21, 2011
Completion Date
August 1, 2011
Last Updated
February 8, 2022
NCT04550494
NCT07144826
NCT06855706
NCT06295965
NCT04919629
NCT03428802
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions